$1.47
2.00% yesterday
NYSE, Sep 12, 10:10 pm CET
ISIN
US44486Q1031
Symbol
HUMA

Humacyte Stock price

$1.47
-0.33 18.11% 1M
-1.52 50.84% 6M
-3.58 70.89% YTD
-4.15 73.84% 1Y
-3.01 67.19% 3Y
-8.20 84.80% 5Y
-8.20 84.80% 10Y
-8.20 84.80% 20Y
NYSE, Closing price Fri, Sep 12 2025
-0.03 2.00%
ISIN
US44486Q1031
Symbol
HUMA
Industry

Key metrics

Basic
Market capitalization
$232.8m
Enterprise Value
$211.8m
Net debt
positive
Cash
$38.0m
Shares outstanding
156.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
283.9 | 35.6
EV/Sales
258.3 | 32.4
EV/FCF
negative
P/B
57.5
Financial Health
Equity Ratio
-38.4%
Return on Equity
281.1%
ROCE
-94.1%
ROIC
-117.7%
Debt/Equity
4.2
Financials (TTM | estimate)
Revenue
$820.0k | $6.5m
EBITDA
$-103.7m | $-60.5m
EBIT
$-111.0m | $-102.2m
Net Income
$-59.0m | $-39.5m
Free Cash Flow
$-105.8m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-4.1% | 43.4%
EBIT
-3.9% | 10.4%
Net Income
57.9% | 73.5%
Free Cash Flow
-28.6%
Margin (TTM | estimate)
Gross
55.9%
EBITDA
-12,691.6% | -925.3%
EBIT
-13,586.3%
Net
-7,221.5% | -603.7%
Free Cash Flow
-12,948.6%
More
EPS
$-0.4
FCF per Share
$-0.7
Short interest
24.4%
Employees
219
Rev per Employee
$0.0
Show more

Is Humacyte a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,008 stocks worldwide.

Humacyte Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Humacyte forecast:

10x Buy
83%
2x Hold
17%

Analyst Opinions

12 Analysts have issued a Humacyte forecast:

Buy
83%
Hold
17%

Financial data from Humacyte

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
0.82 0.82
-
100%
- Direct Costs 0.36 0.36
-
44%
0.46 0.46
-
56%
- Selling and Administrative Expenses 31 31
33% 33%
3,743%
- Research and Development Expense - -
-
-
-104 -104
4% 4%
-12,645%
- Depreciation and Amortization 7.31 7.31
1% 1%
891%
EBIT (Operating Income) EBIT -111 -111
4% 4%
-13,537%
Net Profit -59 -59
58% 58%
-7,195%

In millions USD.

Don't miss a Thing! We will send you all news about Humacyte directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Humacyte Stock News

Neutral
Seeking Alpha
about one month ago
I maintain my Sell rating on Humacyte due to slow SYMVESS adoption, missed Q2 estimates, and ongoing operational challenges. SYMVESS's limited market, negative publicity, and CMS reimbursement hurdles highlight significant barriers to broader commercial success. In my opinion, HUMA's cash runway extends only into early 2026, with ongoing dilution and a likely need for additional financing soon.
Neutral
Seeking Alpha
about one month ago
Humacyte, Inc. (NASDAQ:HUMA ) Q2 2025 Earnings Call August 11, 2025 8:00 AM ET Company Participants Dale A. Sander - CFO, Chief Corporate Development Officer & Treasurer Laura E.
Neutral
GlobeNewsWire
about one month ago
- Total revenues of $301,000 for quarter, and $818,000 for first six months of 2025, from sales and collaborative research agreement - - 82 civilian hospitals now have VAC approval to purchase Symvess™ - - ECAT approval makes Symvess available to 35 Military Treatment Facilities and 160 U.S. Department of Veterans Affairs hospitals - - Conference call today at 8:00 am ET - DURHAM, N.C., Aug. 11...
More Humacyte News

Company Profile

Humacyte, Inc. engages in the business of developing and manufacturing off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs, and organ systems with the goal of improving the lives of patients and transforming the practice of medicine. The company was founded by Laura E. Niklason, Shannon Dahl, and Juliana L. Blum on October 13, 2004 and is headquartered in Durham, NC.

Head office United States
CEO Laura Niklason
Employees 219
Founded 2004
Website humacyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today